Talphera, Inc. (TLPH)
- Previous Close
1.1200 - Open
1.0800 - Bid 1.0200 x 100
- Ask 1.0900 x 100
- Day's Range
1.0200 - 1.0800 - 52 Week Range
0.4300 - 1.6100 - Volume
39,880 - Avg. Volume
102,400 - Market Cap (intraday)
17.818M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.13
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
talphera.com15
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: TLPH
Performance Overview: TLPH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLPH
Valuation Measures
Market Cap
17.82M
Enterprise Value
7.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.01
Price/Book (mrq)
1.26
Enterprise Value/Revenue
11.54
Enterprise Value/EBITDA
-0.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.10%
Return on Equity (ttm)
-57.28%
Revenue (ttm)
651k
Net Income Avi to Common (ttm)
-10.29M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.21M